Freedom251 › AI Drug Discovery Software
AlgoraeOS
Facts from AlgoraeOS's own pages
- Benchmarking
- The company says AOS2 outperformed representative state-of-the-art models in published benchmarks. · algoraepharma.com, 14 Nov 2026
- Closed-loop design
- Discovery and pre-clinical development data continuously feed back to strengthen the platform's predictive capability. · algoraepharma.com, 14 Nov 2026
- Current candidates
- The site identifies AI-116 and AI-168 as priority licensing candidates. · algoraepharma.com, 14 Nov 2026
- Data inputs
- The platform connects pre-clinical, clinical, chemical and biological data to generate drug-combination candidates. · algoraepharma.com, 14 Nov 2026
- Dose-response models
- AlgoraeOS models dose-response surfaces using Bliss, Loewe, HSA and ZIP. · algoraepharma.com, 14 Nov 2026
- Headquarters
- Algorae lists its address in Melbourne, Victoria, Australia. · algoraepharma.com, 14 Nov 2026
- Independent validation
- Independent wet-lab validation at Peter MacCallum Cancer Centre tested 21 drug-drug targets across four cancer cell lines, generating approximately 10,000 data points. · algoraepharma.com, 14 Nov 2026
- Intellectual property
- Algorae states that the platform's intellectual property is 100% owned by the company. · algoraepharma.com, 14 Nov 2026
- Licensing and co-development
- Validated candidates are available for out-licensing and co-development with pharmaceutical and biotech partners. · algoraepharma.com, 14 Nov 2026
- Prediction scale
- The platform has generated 500,000 drug-cell line predictions across 3,000+ drugs and 170 cancer cell lines. · algoraepharma.com, 14 Nov 2026
- Purpose
- AlgoraeOS is an AI-powered drug discovery platform that generates drug-combination candidates for licensing and co-development. · algoraepharma.com, 14 Nov 2026
- Research infrastructure
- The UNSW Data Science Hub provides data analysis tools and access to high-performance computing infrastructure for the collaboration. · algoraepharma.com, 14 Nov 2026
- Research partners
- Named research partners are UNSW AI Institute, CSIRO/Data61 and Peter MacCallum Cancer Centre. · algoraepharma.com, 14 Nov 2026
- Training data
- AlgoraeOS was trained on more than 5.5 million unique inhibition records, approximately 11 million with augmentation. · algoraepharma.com, 14 Nov 2026
Where AlgoraeOS stands on Freedom251
- AI Drug Discovery Software#8 of 33